Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
PZ HTL SA

Collaboration to Provide Clinical Trial Services in the United Kingdom for Study Data Capture, Processing, and Reporting

By BiotechDaily International staff writers
Posted on 25 Feb 2013
Merge Healthcare, Inc. (Chicago, IL, USA), a provider of clinical systems, announced that NorthWise Services (NWS; Sittingbourne, UK) has collaborated with Merge and selected eClinical OS (operating system) to gather, manage, and report on clinical trials data across all studies.

NWS is a specialist contract research organization (CRO) providing services in data management, statistics, and medical writing. Its services are complementary to the offerings of Merge, which has allowed a strong and active working partnership to develop.

“NWS has always supported products at the forefront of eClinical technology, but in the past this tended to be separated into different software tools for EDC, ePRO, IVR, etc.,” explained Dr. Philip North, managing director of NorthWise Services. “It is therefore very appealing now to be able to access a wide range of eClinical functions on a single web-based platform, with just one user login and password.”

Recognizing the potential benefits of eClinical OS in collecting, managing, and reporting clinical trials data across all stages, NWS has arranged to have its own eClinical OS-certified study builder, who can now build studies for clients using eClinical OS.

“We were pleased with how easy it was for our study builder to become qualified and certified in the use of eClinical OS,” continued Dr. North. “Merge provided NWS access to eClinical OS in a sandbox environment during the self-training process. Because of this, the qualification was quickly and entirely achieved, using only the extensive online training materials available within eClinical OS. The built-in training materials were intuitive and thorough. Our staff did not require any additional help from Merge—though that would have been available if needed.”

Cost transparency using eClinical OS’s self-service quoting tool was also a benefit to NWS. “The cost calculator tool has been very valuable,” added Dr. North. “Not only is Merge eClinical OS competitive in the eClinical marketplace, but this tool allows us to remain competitive when bidding on a new study with our sponsor clients.”

“With eClinical OS, NWS has deep visibility into the cost of its studies,” said Justin Dearborn, president of Merge Healthcare. “We designed a cost calculator into the system which allows our clients to generate their own quotes and create budget scenarios in real-time. This provides them with the decision support tools to balance options and costs.”

Merge eClinical OS provides end-to-end study support through a single, easy-to-use interface allowing clients to manage and run studies more effectively. It provides built-in study templates, libraries, and reports to help users create studies quickly and manage them effectively without technical, assistance. Merge eClinical OS works for the largest and smallest studies, has the flexibility to support trials in any phase, and captures any type of data, from any source, from any modality.

Merge’s enterprise and cloud-based systems for image intensive specialties provide access to any image, 24/7. Merge also provides health stations, clinical trials software and other health data and analytics solutions that engage consumers in their personal health.

NorthWise Services provides a range of services, including data management, statistics, and medical writing, to the biotechnology, pharmaceutical, and other industries, and other products and services through strategic working alliances.

Related Links:
Merge Healthcare
NorthWise Services


Channels

Genomics/Proteomics

view channel
Image: The TheraCyte cell encapsulation device (Photo courtesy of TheraCyte, Inc.).

Encapsulated Human-Insulin-Producing Progenitor Cells Cure Diabetes in Mouse Model

A breakthrough system that allows subcutaneous implantation of encapsulated immature pancreatic cells (beta progenitor cells) was shown to produce enough insulin to correct the symptoms of diabetes in a mouse model.... Read more

Drug Discovery

view channel
Image: Chitosan is derived from the shells of shrimp and other sea crustaceans, including Alaskan pink shrimp, pictured here (Photo courtesy of NOAA - [US] National Oceanic and Atmospheric Administration).

Chitosan Treatment Clears the Way for Antibiotics to Eliminate Recurrent Urinary Tract Infections

Recurrent urinary tract infection was successfully resolved in a mouse model by treatment with the exfoliant chitosan followed by a round of antibiotics. Bacterial urinary tract infection (UTI), most... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.